Pharmafile Logo
Pharmafocus logo
Advanced Search

Takeda

Showing 15 posts of 249 posts found.

Takeda financials show why the Shire deal was needed

May 14, 2018
Sales and Marketing Shire, Takeda, biotech, drugs, pharma, pharmaceutical

After posting its financials from 2017 and its guidance for the year to come, it’s clear to see why Takeda …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, GSK, J&J, JJ, Novartis, Shire, Takeda, Valeant, biotech, drugs, pharma, pharmaceutical

It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …

News
takeda_global_hq

It’s official: Takeda to buy Shire for £46 billion

May 8, 2018
Manufacturing and Production, Sales and Marketing Shire, Takeda, acquisition, pharma

After more than a month of uncertainty, Takeda has finally confirmed it has managed to successfully acquire Shire, agreeing on …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

News
jon_neal-1_0

Takeda announces new UK MD, ahead of Shire transformation

May 1, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, Takeda, appointment, pharma

“Jon’s appointment comes at an exciting time for the company” reads the company press on annoucing its new Managing Director …

Appointment
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, Fresenius, Shire, Takeda, arthritis, pharma

The year seems like it’s running away as we come to the end of April. It’s been a more tense …

News

Takeda announce new UK MD, ahead of possible Shire transformation

April 26, 2018
Medical Communications Shire, Takeda, biotech, drugs, pharma, pharmaceutical

“Jon’s appointment comes at an exciting time for the company” reads the company press on annoucing its new Managing Director …

News
china_block_001_takeda

$64bn Takeda-Shire mega merger inches closer to closing

April 25, 2018
Research and Development, Sales and Marketing Shire, Takeda, biotech, drugs, pharma, pharmaceutical

From March onwards, Takeda has been nudging a deal with Shire onwards through repeatedly improved offers, which has seen the …

News
pharmafocus_may_2018_cover

The May 2018 issue of Pharmafocus is now live!

April 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar tax

Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

News

Allergan out but Takeda sticks to guns on Shire

April 20, 2018
Medical Communications, Sales and Marketing Allergan, Shire, Takeda, biotech, drugs, pharma, pharmaceutical

Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that …

News
shire_image

Shire jettisons oncology unit for $2.4bn, unbalancing Takeda deal

April 16, 2018
Sales and Marketing Servier, Shire, Takeda, biotech, drugs, oncology, pharma, pharmaceutical

Shire has announced that it has entered a definitive agreement for French drugmaker Servier to take on its oncology business. …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 13, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten

It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …

News
china_block_001_takeda

Takeda move for Shire looks increasingly likely

April 6, 2018
Medical Communications, Sales and Marketing Japan, Shire, Takeda, UK, biotech, drugs, pharma, pharmaceutical

Takeda’s surprise announcement, just last week, that it was weighing up a move for Shire had some analysts sceptical about …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 29, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ablynx, Cancer, GSK, Hemlibra, MSD, Roche, Sun Pharma, Takeda, brexit, pharma, tecentriq, top ten

As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026